Incidental anal 18fluorodeoxyglucose uptake: Should we further examine the patient?

Abstract

BACKGROUND

There are no studies on incidental anal ¹⁸F-fluorodeoxyglucose (¹⁸FDG) uptake.

AIM

To assess the rate and aetiologies of incidental anal ¹⁸FDG uptake and to evaluate the correlation between ¹⁸FDG positron-emission tomography/computed tomography (PET/CT) parameters and the diagnosis of an anorectal disease.

METHODS

The data from patients with incidental anal ¹⁸FDG uptake were retrospectively analysed. Patients who underwent anorectal examinations were identified and compared to those who did not undergo examinations. Patients who were offered treatment were then identified and compared to those who did not receive treatment.

RESULTS

Among the 43020 ¹⁸FDG PET/CT scans performed, 197 ¹⁸FDG PET/CT scans of 146 patients (0.45%) reported incidental anal uptake. Among the 134 patients included, 48 (35.8%) patients underwent anorectal examinations, and anorectal diseases were diagnosed in 33 (69.0%) of these patients and treated in 18/48 (37.5%) patients. Among the examined patients, those with a pathology requiring treatment had significantly smaller metabolic volumes (MV) 30 and MV41 values and higher maximal and mean standardized uptake value measurements than those who did not require treatment.

CONCLUSION

Incidental anal ¹⁸FDG uptake is rare, but a reliable anorectal diagnosis is commonly obtained when an anorectal examination is performed. The diagnosis of an anorectal disease induces treatment in more than one-third of the patients. These data should encourage practitioners to explore incidental anal ¹⁸FDG uptake systematically.

Key Words: Incidental anal ¹⁸fluorodeoxyglucose uptake; Anorectal disease; Rare

Core tip: This is a retrospective study to assess the rate and aetiologies of incidental anal ¹⁸F-fluorodeoxyglucose (¹⁸FDG) uptake and to evaluate the correlation between ¹⁸FDG positron-emission tomography/computed tomography parameters and the diagnosis of an anorectal disease. Incidental anal ¹⁸FDG uptake is rare, but a reliable anorectal diagnosis is commonly obtained when an anorectal examination is performed. The diagnosis of an anorectal disease induces treatment in more than one-third of the patients. These data should encourage practitioners to explore incidental anal ¹⁸FDG uptake systematically.

INTRODUCTION

¹⁸F-fluorodeoxyglucose (¹⁸FDG) positron-emission tomography/computed tomography (PET/CT) is a medical imaging technique based on the study of glucose metabolism. The use of this method has increased in oncology for the initial staging of cancer, monitoring treatment response and detecting early recurrence of a previously treated malignant tumour[1]. It is also used in the management of infectious or inflammatory diseases[2]. As a result of the increased indications for and availability of ¹⁸FDG PET/CT, unexpected ¹⁸FDG uptake has been identified in a variety of sites[3-6]. In the field of gastroenterology, several studies have focused on colorectal locations[7-17]. Incidental focal colorectal ¹⁸FDG uptake on ¹⁸FDG PET/CT imaging was associated with endoscopic lesions in two-thirds of the cases, with a high rate of advanced neoplasms[7], but no metabolic parameter has been identified to distinguish neoplasms from benign lesions[7,18]. Thus, a complete colonoscopy tends to be recommended for all patients.

Within the field of gastroenterology, no studies to date have investigated incidental anal ¹⁸FDG uptake. However, anorectal examinations are nevertheless simple and minimally invasive, and the diagnosis of anal pathologies is often based on the patient’s history or data obtained during the clinical examination. It seems important then to assess the rate of incidental anal ¹⁸FDG uptake and to identify their aetiologies. Finally, no recommendations have been established in this particular situation.

The aims of this study were as follows: (1) To assess the rate of incidental anal ¹⁸FDG uptake; (2) To identify the aetiologies of incidental anal ¹⁸FDG uptake; and (3) To evaluate the correlation between ¹⁸FDG PET/CT parameters and the diagnosis of an anorectal disease and the management of the disease.

MATERIALS AND METHODS

Patients

The database of ¹⁸FDG PET/CT scans from a tertiary referral centre of nuclear medicine (January 2005 and December 2018) was reviewed. Among 43020 ¹⁸FDG PET/CT reports, those containing the terms “anal” or “anus” were identified. Then, we selected examinations with incidental anal ¹⁸FDG uptake. Patients with personal histories of anal cancer were excluded. Patients with a history of pelvic radiation within 3 months or anal surgery within 6 weeks before the ¹⁸FDG PET/CT were also excluded. The patient demographic data, past medical histories, indications for ¹⁸FDG PET/CT and results concerning the initial oncological pathology report were extracted from the database.

¹⁸FDG PET/CT imaging protocol and analysis

The patients fasted for at least 4 hours before ¹⁸FDG PET/CT imaging. The blood glucose level was controlled before the FDG injection. The acquisition ranged from the base of the skull to the proximal thighs and was performed 60 to 90 min after an intravenous injection of FDG. From January 2005 to May 2016, ¹⁸FDG PET/CT exams were performed with a hybrid PET/CT scanner (Discovery LS, GE Medical Systems Inc., Waukesha, WI, United States) after an intravenous injection of 4 MBq/kg FDG. From June 2016 to December 2018, ¹⁸FDG PET/CT exams were performed with a hybrid PET/CT scanner (Siemens Biograph system, Siemens, Knoxville, TN, United States) after an intravenous injection of 3 MBq/kg FDG. For both PET systems, the data were reconstructed using an ordered-subsets expectation maximization iterative algorithm with corrections (attenuation, dead time, randoms, scatter, and decay). The standardized uptake value (SUV) was calculated and adjusted by the mean injected dose according to the tissue activity concentration and patient body weight. To include patients with focal incidental anal ¹⁸FDG uptake, all ¹⁸FDG PET/CT images from patients identified with incidental anal uptake were retrospectively reassessed by a nuclear medicine physician at the Department of Nuclear Medicine who was blinded to the anorectal findings. Anal ¹⁸FDG uptake was defined as uptake located in the anal canal relative to the background activity. Incidental anal ¹⁸FDG uptake was defined by the existence of anal hyperfixation in patients with no known anal pathology before the ¹⁸FDG PET/CT. A 3-D volume of interest (VOI) was manually drawn to extract metabolic parameters (Syngo.via software; Siemens). The metabolic parameters extracted were the SUV_max (the highest SUV of all SUVs measured in the VOI), SUV_mean (the mean of all SUV_mean measurements from the tumour VOIs with a local SUV_max threshold of 41%), and different metabolic volumes (MVs) defined as the volume produced by segmentation at the following fixed SUV_max thresholds: 50% (MV50), 41% (MV41), and 30% (MV30)[1,14]. In patients with anal uptake described on several ¹⁸FDG PET/CT scans, the metabolic parameters selected were those that corresponded to the ¹⁸FDG PET/CT with the largest SUV_max.

Management of incidental anal ¹⁸FDG uptake

The data about management after the discovery of incidental anal ¹⁸FDG uptake were collected from the patient records from the Department of Nuclear Medicine. The data were compared with the patient records from the general practitioner and/or the specialist, if applicable.

The data collected from patients who further investigated were as follows: Symptoms, practitioner who performed the evaluation (oncologist, radiotherapist, surgeon, gastroenterologist, or colorectal specialist), evaluation modality (rectal examination, anoscopy), further examinations (CT scan, magnetic resonance imaging, endoanal ultrasound, and examinations under general anaesthesia, colonoscopy, or histology) and results, if available. The diagnosis was recorded and classified as follows: Haemorrhoidal disease, anal fissure, neoplasia, fistula, anal condyloma, or other diagnosis. Each proctologic report was reviewed by a specialist in proctology from the University Hospital of Rennes. Treatments were offered in case of symptomatic disease or if there was a risk of extension and/or aggravation of the disease. The treatment was chosen according to the habits of the practitioner. Patients who were offered treatment were identified and compared to those who were not treated. The proposed treatments were collected.

Among the patients with incidental anal ¹⁸FDG uptake, the patient data were compared according to the occurrence of anorectal investigations.

Statistical analyses

The quantitative variables are presented as means and percentiles (interquartile range of 25% and 75%). The qualitative variables are presented as numbers and percentages. The qualitative variables were compared using χ² tests or Fischer’s exact tests, as appropriate. The quantitative variables were compared using the non-parametric Wilcoxon’s test. Comparisons between patients who underwent examinations with those who had not were performed using the Wilcoxon test and the χ² test or Fisher’s exact test, as appropriate. The same tests were applied to compare patients who were offered treatment with those who were not. A P value < 0.05 was considered statistically significant. To measure the discriminatory accuracy of SUV and MV for diagnostic and therapeutic management, a receiver operating characteristic (ROC) analysis was performed, and the area under the ROC curve (AUROC) was calculated. Logistic regression analysis was performed with independent categorical items obtained at P < 0.05 by univariate analysis using a forward method to identify factors associated to treatment. Pearson correlation coefficients and Fisher tests were performed to verify whether the Pearson coefficients were significantly different from 0. The tests were performed using JMP Pro software, version 13.0.0 (SAS, Cary, NC, United States).

RESULTS

Overall study population

Among the 43020 ¹⁸FDG PET/CT scans performed between January 2005 and December 2018, 197 ¹⁸FDG PET/CT of 146 patients reported incidental anal uptake. Twelve patients were excluded; finally, 134 patients were included in the study (Figure 1). The patient characteristics and ¹⁸FDG PET/CT indications are summarized in Table 1. Twenty-one (15.7%) patients had the following past anorectal histories: Haemorrhoidal disease (7.8%), anal fistula (4.7%), anal fissure (1.6%), anal condyloma (1.6%), and faecal incontinence (0.7%).

Table 1 Characteristics of the global population (n = 134).

Variables	Global population	Patients non investigated	Patients investigated	P value
	n (%) or mean ± SD	n (%) or mean ± SD	n (%) or mean ± SD
	n = 134	n = 86	n = 48
Age (yr)	61.3 (12.8)	61.0 (12.1)	61.9 (14.1)	0.69
Gender (male)	84 (62.7)	56 (65.1)	28 (58.3)	0.43
18FDG PET/CT indications				0.42
Diagnosis	20 (14.9)	10 (11.6)	10 (20.8)
Follow-up of a known cancer	47 (35.1)	32 (37.2)	15 (31.3)
Staging of a known cancer	45 (33.6)	32 (37.2)	13 (27.1)
Suspicion of cancer recurrence	17 (12.7)	9 (10.5)	8 (16.7)
Diagnosis of infectious/inflammatory disease	5 (3.7)	3 (3.5)	2 (4.2)
Primitive cancer				0.13
Hematological cancer	22 (16.4)	17 (20.0)	5 (10.5)
Head and neck cancer	14 (10.4)	9 (10.5)	5 (10.4)
Lung cancer	25 (18.6)	21 (24.4)	4 (8.3)
Gynecological cancer	22 (16.4)	13 (15.1)	9 (18.8)
Urological cancer	4 (3.0)	1 (1.1)	3 (6.3)
Digestive cancer	14 (10.5)	8 (3.5)	6 (12.5)
Melanoma	9 (6.7)	5 (5.8)	4 (8.3)
Others1	7 (5.2)	3 (3.5)	4 (8.3)
Past history of pelvic radiotherapy2	13 (9.7)	8 (9.3)	5 (10.4)	0.83
Past history of proctologic diseaseb	21 (15.7)	6 (7.0)	15 (31.3)	0.0002
18FDG PET/CT
SUV mean	5.5 (2.3)	5.3 (2.1)	5.9 (2.6)	0.15
SUV max	9.6 (3.9)	9.2 (3.5)	10.2 (4.5)	0.13
MV50 (cm3)	4.1 (2.8)	4.2 (3.0)	4.0 (2.3)	0.65
MV41 (cm3)	6.6 (4.2)	6.7 (4.6)	6.4 (3.5)	0.64
MV 30 (cm3)	11.9 (7.1)	12.2 (7.7)	11.4 (5.9)	0.51

^bP < 0.01.

¹Others: sarcoma, neuroendocrine carcinoma, neurological cancer, carcinoma unknown primary syndrome.

²> 3 mo before fluorodeoxyglucose positron emission tomography with computed tomography.

¹⁸F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography; SUV: Maximum standardized uptake value; MV: Metabolic volume.

Figure 1 Flow chart. Among the 144 patients with non-incidental uptake, 121 had known anal cancer; 14 had pelvic cancer with known anal extension; 2 had a known abnormality on anorectal examination at the time of the positron emission tomography with computed tomography; 7 had recent pelvic radiotherapy or surgery. PET/CT: Positron emission tomography with computed tomography.

Patients who underwent anorectal examinations

Among the 134 patients with incidental anal ¹⁸FDG uptake, 48 (35.8%) underwent anorectal examinations to explore the anomaly. The characteristics of the patients who underwent examinations are depicted in Table 1 and Table 2. The patients were examined most frequently by a colorectal specialist (62.5%) or a gastroenterologist (20.8%). The clinical examinations ranged from a simple inspection of the anal margin (95.8%) to anoscopy (51.1%). More than half (54.2%) of the patients had at least one other examination. Patients who underwent examinations were compared with those who did not undergo examinations (Table 1). The two groups were comparable in terms of age, sex, indication for ¹⁸FDG PET/CT, primitive cancer, history of pelvic radiotherapy and ¹⁸FDG PET/CT metabolic parameters. Patients who underwent examinations more frequently had a past history of anorectal disease than those who did not undergo examinations (P = 0.0002). Among the 48 patients who underwent examinations, 33 (69%) had the following anorectal diseases: Haemorrhoidal disease (n = 19), anal fissure (n = 6), recurrence of rectal adenocarcinoma on the coloanal anastomosis (n = 2), condyloma (n = 3), faecal impaction (n = 1), suppuration (n = 1) and solitary rectal ulcer syndrome (n = 1) (Figure 2).

Table 2 Characteristics of population investigated (n = 48).

	All	No treatment offered	Treatment offered	P value
	n (%) or mean ± SD	n (%) or mean ± SD	n (%) or mean ± SD
	n = 48	n = 30	n = 18
Assessmenta by				0.0457
Proctologist	30 (62.5)	15 (50.0)	15 (83.3)
Gastroenterologist	10 (20.8)	7 (23.3)	3 (16.7)
Oncologist	2 (4.2)	2 (6.7)
Radiotherapist	5 (10.4)	5 (16.7)
Surgeon	1 (2.1)	1 (3.3)
Examination
Anal margin	46 (95.8)	29 (96.7)	17 (94.4)	0.71
Rectal digital examination	40 (85.2)	25 (86.2)	15 (83.3)	0.78
Anoscopy	24 (51.1)	12 (41.4)	12 (66.7)	0.09
Colonoscopy	17 (36.2)	11 (38.0)	6 (33.3)	0.75
Examination under general anesthesiaa	5 (10.6)	1 (3.5)	4 (22.2)	0.04
Biopsies	8 (17.0)	3 (10.3)	5 (27.8)	0.12
Endoanal ultrasound	7 (14.9)	5 (17.2)	2 (11.1)	0.56
Pelvic MRI	2 (4.3)	1 (3.5)	1 (5.6)	0.73
Symptom	19 (40.4)	9 (31.0)	10 (58.8)	0.06
18FDG PET/CT
SUV meana	5.9 (2.6)	5.2 (1.9)	7.2 (3.2)	0.02
SUV maxa	10.2 (4.5)	9.0 (3.3)	12.4 (5.4)	0.02
MV50	4.0 (2.3)	4.4 (2.4)	3.3 (2.0)	0.13
MV41	6.4 (3.5)	7.2 (3.6)	5.1 (3.0)	0.05
MV 30a	11.4 (6.0)	12.9 (6.3)	8.9 (4.4)	0.03
Diagnosis of a proctological diseaseb	33 (68.8)	15 (50.0)	18 (100.0)	0.003
Haemorrhoidal disease	19	2	12
Anal fissure	6	1	5
Recurrence of rectal adenocarcinoma	2	0	2
Condyloma	3	1	2
Fecal impaction	1	1	0
Anal suppuration	1	0	1
Solitary rectal ulcer syndrome	1	0	1
Treatment	18 (37.5)		18 (100)
Medical treatment			11 (61.1)
Surgical treatment			5 (27.8)
Medical and instrumental treatments			1 (5.6)
Endoscopic treatment			1 (5.6)

^aP < 0.05;

^bP < 0.01. MRI: Magnetic resonance imaging;

¹⁸F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography; SUV: Maximum standardized uptake value; MV: metabolic volume.

Figure 2 Incidental anal ¹⁸F-fluorodeoxyglucose uptake. A: An incidental anal ¹⁸F-fluorodeoxyglucose uptake in 1 study patient with hemo rrhoidal disease that required medical treatment (standardized uptake value max = 18.1); B: An incidental anal ¹⁸F-fluorodeoxyglucose uptake in 1 study patient without proctological diagnosis (standardized uptake value max = 4.9); C: An incidental anal ¹⁸F-fluorodeoxyglucose uptake in 1 study patient with hemorrhoidal disease that did not require treatment (standardized uptake value max = 8.8).

In our study group, no metabolic parameters were significantly associated with the presence or absence of a diagnosis; likewise, there were no significant differences between anorectal diseases according to the metabolic parameters.

Treated patients and therapeutic impact of metabolic parameters

Among the 48 patients who underwent examinations, 18 (37.5%) were offered treatment (Table 3). The characteristics of the treated patients were compared with those of the untreated patients and are depicted in Table 2. All patients who received treatment had more frequent complaints than those who did not receive treatment and were examined by colorectal specialists or gastroenterologists. Of the asymptomatic patients, 18/29 were diagnosed [haemorrhoidal disease (n = 12), anal fissure (n = 2), condyloma (n = 3) and solitary rectal ulcer syndrome (n = 1)] and 8/29 were offered treatment. Among the 29 asymptomatic patients, the ¹⁸FDG PET/CT metabolic parameters differed significantly between treated and untreated patients. The group of asymptomatic patients that was offered treatment had higher SUV_max and SUV_mean measurements (P = 0.03 for both) and lower MV41 and MV30 values than the group asymptomatic patients without treatment (P = 0.02 and P = 0.03, respectively). Among the 15 patients with progressive PET-CT (considered poor prognosis), 8 had treatment and 7 had no treatment (P = 0.46). The ¹⁸FDG PET/CT metabolic parameters differed significantly between treated and untreated patients. The group of patients that was offered treatment had higher SUV_max and SUV_mean measurements (P = 0.02 for both) and lower MV41 and MV30 values than the group without treatment (P = 0.05 and P = 0.03, respectively). The ROC curves of the SUV_max, SUV_mean, MV41 and MV30 as predictive factors for the treatment of examined incidental anal ¹⁸FDG uptake are shown in Figure 3. According to the ROC curves, the optimal cut-off for SUV_max, SUV_mean, MV41 and MV30 were 9.6, 6.1, 3.1 cm³ and 7.4 cm³, respectively. The SUV_max measurements were inversely correlated with MV41 (r = -0.27, P = 0.0006) and MV30 (r = -0.18, P = 0.0002). In a multivariate analysis including the presence of symptoms, the diagnosis (yes) and the SUV _mean > 6.1 cm³, the factor significantly associated with the treatment was the SUV _mean > 6.1 cm³ [OR = 6.87 (1.18-29.9), P = 0.03].

Table 3 Treatments.

	n (%)
Total	18 (100)
Medical treatment	11 (61.1)
Transit regulator	4 (22.2)
Oral analgesic treatment	1 (5.6)
Topical treatment	8 (44.4)
Treatment of hemorrhoids	4 (22.2)
5-aminosalicylic acid	1 (5.6)
Antibiotic (metronidazole)	1 (5.6)
Botulinum toxin injection	1 (5.6)
Healing cream	1 (5.6)
Surgical treatment	5 (27.9)
Electrocoagulation of condyloma	1 (5.6)
Surgery of hemorrhoids	2 (11.1)
Fissurectomy	1 (5.6)
Posterior pelvectomy	1 (5.6)
Instrumental and medical treatment
Infrared coagulation and imiquimod	1 (5.6)
Endoscopic treatment
Hydraulic dilatation	1 (5.6)

Figure 3 Receiver operating characteristic curve. A: Standardized uptake value mean; B: Standardized uptake value max; C: Metabolic volumes 41; D: Metabolic volumes 30, to differentiate patients requiring treatment from others. AUC: Area under the curve.

DISCUSSION

To the best of our knowledge, this is the first study to evaluate the rate of incidental anal ¹⁸FDG uptake and its diagnostic and therapeutic impact in a large series of ¹⁸FDG PET/CT scans performed over a 14-year period.

The present work highlights that incidental anal ¹⁸FDG uptake is a rare event (0.45%) and is not systematically explored (36%). When examinations are performed, an anorectal disease was diagnosed in more than two-thirds of the patients (69%), and a specific treatment was proposed in almost 40% of these patients. Finally, we identified some metabolic parameters (SUV_max, SUV_mean, MV41 and MV30) significantly associated with anorectal treatment, with SUV_max having the best accuracy. Taken together, our data suggest that, although it is not frequent, incidental anal ¹⁸FDG uptake should require anorectal examinations given its high diagnostic and therapeutic impact.

The main strengths of this work are the inclusion of a large number of ¹⁸FDG PET/CT scans requested for various indications over a long period of time, reassessment of ¹⁸FDG PET/CT images by a physician who was blinded to anorectal findings and exhaustiveness of the anorectal data collection. As previously mentioned, this is also, to the best of our knowledge, the first study to investigate the rate and management of incidental anal ¹⁸FDG uptake.

In our series, incidental anal ¹⁸FDG uptake was investigated in 36% of the patients, which means that it was not been taken into account in almost two-thirds of the patients. Several explanations are possible. First, incidental anal ¹⁸FDG uptake was not mentioned in the conclusion but only in the details of the ¹⁸FDG PET/CT report of many patients (58%), which suggests that many nuclear physicians considered this ¹⁸FDG uptake to be non-clinically significant in the absence of data in the current literature. Furthermore, very few reports of consultations with the referring physician who prescribed the ¹⁸FDG PET/CT mentioned the anal ¹⁸FDG uptake, which may be explained by the following points: (1) No mention of the anal ¹⁸FDG uptake in the conclusion of the ¹⁸FDG/PET CT report; (2) The physician (an oncologist in the majority of cases) considered that the anal ¹⁸FDG uptake was secondary compared to the pathology that motivated the ¹⁸FDG PET/CT (tumour diagnosis, recurrence or progression), regardless of whether the patients underwent examinations, and was comparable in each setting and (3) The physician did not dare to discuss this abnormality with the patient or the patient refused to be examined, as we know that anorectal complaints and examinations remain a taboo subject for both patients and physicians.

Importantly, patients who were examined underwent a specific anorectal treatment in almost 40% of the cases, including surgery in 28% (5/18) of these cases. Therefore, it seems justified to systematically seek anorectal complaints and propose an anorectal examination, which should include at least an anal margin and rectal digital examination. This first assessment is simple and minimally invasive and makes it possible to evaluate if the patient needs to be referred to a specialist. However, this strategy cannot assess haemorrhoidal diseases with enough sensitivity. Notably, 40% of the examined patients in the present study had anorectal symptoms, which emphasizes the importance of a obtaining a good patient history to identify those who need to be directly addressed to a colorectal specialist.

Our study identified SUV and MV measurements as factors associated with the anorectal examination having a therapeutic impact, with SUV_max having the best accuracy. Interestingly, patients who received treatment had significantly lower MV30 and MV41 values and higher SUV_max and SUV_mean measurements than patients who did not receive treatment. These conclusions are different from those of colorectal positive uptake. In the studies on incidental focal colorectal ¹⁸FDG uptake on ¹⁸FDG PET/CT images, the metabolic parameters could not differentiate between true positives and false positives, with acceptable sensitivity and specificity, and therefore had no diagnostic or therapeutic impact[7,17-19].

In our study, the diagnoses correspond more to inflammatory or infectious processes than to other conditions. In this field, the diagnostic, therapeutic or prognostic impact of metabolic parameters has not been identified, except for SUV_max, which has been shown to have a prognostic impact on cardiovascular events and corticosteroid response in patients with cardiac sarcoidosis[20]. However, in oncology, the metabolic tumour volume (MTV) has a prognostic impact on diseases in several locations (head and neck cancers or anal cancers, for example), with a prognosis that worsens as the MTV increases[1,21-27], which is sometimes also the case for SUV_max[28-31]. These parameters also have a role in monitoring therapy response[1,32-34]. Paradoxically, our results showed that smaller MVs are associated with treatment. We have not found any similar cases in the literature. Additionally, a lesion does not necessarily require more treatment because it has a larger volume.

Our study results, however, should be interpreted with caution for several reasons. The main limitations of this study are its retrospective and monocentric design. Moreover, it is possible that the rate of anal ¹⁸FDG uptake we reported is underestimated because it cannot be excluded that this anomaly is not systematically described by all nuclear physicians, given the lack of clinical significance described so far. In addition, 62% of the patients included did not undergo anorectal examinations; thus, the aetiology of their anal ¹⁸FDG uptake remains unknown. It would have also been interesting to investigate a control group of patients without anal ¹⁸FDG uptake to better demonstrate the diagnostic and therapeutic impact of anal ¹⁸FDG uptake. In our study, the proportions of patients who underwent examinations and those who received treatment were low, which led to a lack of power, even though this is the largest series reported. Due to the small sample size, we were unable to analyse the relationship between metabolic parameters and a precise diagnosis. The role of haemorrhoidal disease in anal ¹⁸FDG uptake remains somewhat speculative since haemorrhoids cushions are a normal compound of anal anatomy. Finally, symptomatic complaints not recorded (retrospective analyses) may bias the results (high proportion of treated anorectal lesions).

In conclusion, incidental anal ¹⁸FDG uptake is a rare event and is rarely explored. However, when explored, a diagnosis is made in more than two-thirds of the cases, and treatment is proposed in more than one-third of the cases. Some metabolic parameters associated with a therapeutic impact have been identified. These data should encourage practitioners to explore incidental anal ¹⁸FDG uptake systematically because some patients may recover well from an anal pathology.

ARTICLE HIGHLIGHTS

Research background

The use of ¹⁸F-fluorodeoxyglucose (¹⁸FDG) positron-emission tomography/computed tomography (PET/CT) has increased in oncology and in the management of infectious or inflammatory diseases. As a result of the increased indications for and availability of ¹⁸FDG PET/CT, unexpected ¹⁸FDG uptake has been identified in a variety of sites. In the field of gastroenterology, several studies have focused on incidental focal colorectal ¹⁸FDG uptake. No studies to date have investigated incidental anal ¹⁸FDG uptake. Anorectal examinations are nevertheless simple and minimally invasive, and the diagnosis of anal pathologies is often based on the patient’s history or data obtained during the clinical examination.

Research motivation

It seems important to assess the rate of incidental anal ¹⁸FDG uptake and to identify their aetiologies. Finally, no recommendations have been established in this particular situation.

Research objectives

The objectives of this study were as follows to assess the rate of incidental anal ¹⁸FDG uptake, to identify the aetiologies of incidental anal ¹⁸FDG uptake, and to evaluate the correlation between ¹⁸FDG PET/CT parameters and the diagnosis of an anorectal disease and the management of the disease.

Research methods

We carried out a retrospective observational single-centre study. The data from patients with incidental anal ¹⁸FDG uptake were analysed. Patients who underwent anorectal examinations were identified and compared to those who did not undergo examinations. Patients who were offered treatment were then identified and compared to those who did not receive treatment. Comparisons between patients were performed using the Wilcoxon test and the chi-squared test or Fisher’s exact test, as appropriate. A P value < 0.05 was considered statistically significant.

Research results

Among the 43020 ¹⁸FDG PET/CT scans performed, 197 ¹⁸FDG PET/CT scans of 146 patients reported incidental anal uptake: The rate of incidental anal ¹⁸FDG uptake was 0.45%. Among the 134 patients included, 48 (35.8%) patients underwent anorectal examinations and anorectal diseases were diagnosed in 33 (69.0%) of these patients haemorrhoidal disease (n = 22), anal fissure (n = 6), recurrence of rectal adenocarcinoma on the coloanal anastomosis (n = 1), condyloma (n = 3), faecal impaction (n = 1), suppuration (n = 2) and solitary rectal ulcer syndrome (n = 1). Eighteen/48 (37.5%) received treatment. Among the examined patients, those with a pathology requiring treatment had significantly smaller metabolic volumes (MV) 30 and MV41 values and higher maximal and mean standardized uptake value measurements than those who did not require treatment.

Research conclusions

Incidental anal ¹⁸FDG uptake is a rare event and is rarely explored. However, when explored, a diagnosis is made in more than two-thirds of the cases, and treatment is proposed in more than one-third of the cases. Some metabolic parameters associated with a therapeutic impact have been identified. These data should encourage practitioners to explore incidental anal ¹⁸FDG uptake systematically because some patients may recover well from an anal pathology.

Research perspectives

Further large-scale prospective studies are needed. We would like to investigate a control group of patients without anal ¹⁸FDG uptake to better demonstrate the diagnostic and therapeutic impact of anal ¹⁸FDG uptake.